Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine

[1]  U. Meyer,et al.  Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.

[2]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[3]  U. Meyer,et al.  The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. , 1990, American journal of human genetics.

[4]  L. Pickle,et al.  DEBRISOQUINE PHENOTYPE AND GENOTYPE IN CHINESE , 1989, The Lancet.

[5]  C. Alm,et al.  Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. , 1989, British journal of clinical pharmacology.

[6]  C. Alm,et al.  Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. , 1989, British journal of clinical pharmacology.

[7]  M. Ingelman-Sundberg,et al.  DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE , 1989, The Lancet.

[8]  T. Ishizaki,et al.  Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.

[9]  L. Bertilsson,et al.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects , 1988, Clinical pharmacology and therapeutics.

[10]  U. Meyer,et al.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. , 1988, Biochemistry.

[11]  R. Skoda,et al.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Bertilsson,et al.  LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION , 1987, The Lancet.

[13]  M. Eichelbaum,et al.  Evidence for polymorphic oxidation of sparteine in Japanese subjects. , 1987, British journal of clinical pharmacology.

[14]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[15]  J. Idle,et al.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.

[16]  M. Eichelbaum,et al.  Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.

[17]  G. Tucker,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE , 1977, The Lancet.

[18]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[19]  K. Brøsen,et al.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism , 2004, European Journal of Clinical Pharmacology.

[20]  A. S. Gross,et al.  The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.